Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | PTGES | O14684 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25583638 | 0.98 | CYP19A1 (0.50) | MAPTPOLBLMNAGAAEPHX2 | |
| SCHEMBL3910348 | 0.98 | CYP19A1 (0.50) | MAPTPOLBLMNAGAAEPHX2 | |
| SCHEMBL25583651 | 0.98 | CYP19A1 (0.50) | MAPTPOLBLMNAGAAEPHX2 | |
| SCHEMBL11044966 | 0.92 | EPHX2 (0.54) | MAPTPOLBLMNAGAAEPHX2 | |
| Formic Acid SCHEMBL28836905 | 0.89 | PARP10 (0.47) | MAPTPOLBLMNAGAAEPHX2 | |
| SCHEMBL4481722 | 0.85 | HRH3 (0.58) | CYP1A2CYP2D6 | |
| SCHEMBL28358940 | 0.84 | EPHX2 (0.49) | MAPTPOLBLMNAGAAEPHX2 | |
| SCHEMBL31378828 | 0.84 | EPHX2 (0.46) | MAPTPOLBLMNAGAAEPHX2 | |
| SCHEMBL30440665 | 0.84 | EPHX2 (0.49) | MAPTPOLBLMNAGAAEPHX2 | |
| SCHEMBL18283502 | 0.84 | EPHX2 (0.46) | MAPTPOLBLMNAEPHX2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017214505-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| EP-3080098-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2017-12-06 | — | — | EP | disclosed |
| EP-3080098-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2017-12-06 | — | — | EP | disclosed |
| US-9802920-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMAN-LA ROCHE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802920-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMAN-LA ROCHE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802920-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMAN-LA ROCHE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| WO-2017153952-A1 | 5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-14 | — | — | WO | disclosed |
| US-20160304497-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | CHUGAI PHARMACEUTICAL CO. (JP) | 2016-10-20 | — | — | US | disclosed |
| US-20160304497-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | CHUGAI PHARMACEUTICAL CO. (JP) | 2016-10-20 | — | — | US | disclosed |
| US-20160304497-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | CHUGAI PHARMACEUTICAL CO. (JP) | 2016-10-20 | — | — | US | disclosed |
| EP-3080098-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. Hoffmann-La Roche AG (CH) | 2016-10-19 | — | — | EP | disclosed |
| CN-105722834-A | Inhibitors of bruton's tyrosine kinase | 豪夫迈·罗氏有限公司 | 2016-06-29 | — | — | CN | disclosed |
| WO-2015086636-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086636-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-18 | — | — | WO | disclosed |
| EP-0335274-B1 | Formation of nitrophenyl ethers from polyols and nitroanisoles | DOW CHEMICAL CO (US) | 1996-03-13 | — | — | EP | disclosed |
| US-4960950-A | Formation of nitrophenyl ethers from polyols and nitroanisoles | THE DOW CHEMICAL COMPANY (US) | 1990-10-02 | — | — | US | disclosed |
| EP-0335274-A2 | Formation of nitrophenyl ethers from polyols and nitroanisoles | THE DOW CHEMICAL COMPANY (US) | 1989-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304497-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | MAPT 3742/4885POLB 1831/4885LMNA 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.